Market Overview

Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology

Share:
Related IMGN
18 Biggest Mid-Day Gainers For Wednesday
15 Stocks Moving In Wednesday's Pre-Market Session
Related LLY
Carl Icahn's Track Record In Big Pharma
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Truxima Fires The Starting Gun In Biosimilar Race To The Bottom (Seeking Alpha)

Immunogen (NASDSAQ: IMGN) shares are rallying in early-afternoon trade Wednesday following a Form 8-K just filed with the SEC.

From the filing: "On August 26, 2013, ImmunoGen, Inc. (referred to as “we,” “us” or the “Company”) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) (“Lilly”) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011. In accordance with the terms of the Multi-Target Agreement, execution of the license agreement entitles us to receive development, regulatory and sales milestone payments potentially totaling $200.5 million, as well as royalties on the commercial sales of any resultant products."

Posted-In: News Movers

 

Related Articles (LLY)

View Comments and Join the Discussion!